alexa Surviving blood loss using hydrogen sulfide.

Journal of Autacoids and Hormones

Author(s): Morrison ML, Blackwood JE, Lockett SL, Iwata A, Winn RK,

Abstract Share this page

Abstract BACKGROUND: Reduced metabolic activity improves outcome in many clinical and experimental models of injury and diseases that result in insufficient blood supply. Recently, we demonstrated that inhaled hydrogen sulfide gas can be used to reversibly reduce metabolic activity in mice. We hypothesize that hydrogen sulfide will confer benefit in injuries and diseases related to insufficient blood supply. METHODS: Sprague-Dawley rats were subjected to controlled hemorrhage to remove 60\% of total blood. Hydrogen sulfide was administered to rats either via airway as gas, or intravenous infusion as liquid. Outcome was assayed by survival. RESULTS: Using inhaled hydrogen sulfide gas, 75\% of treated and 23\% of untreated rats survived longer than 24 hours. Using intravenous administered sulfide, 67\% of treated and 14\% of untreated rats survived longer than 24 hours. Using log-rank analysis, p < 0.001. Surviving rats showed no functional or behavioral abnormalities. Blood chemistry analysis at the end of hemorrhage showed minor but significant differences between treated and control animals. Respirometry results show that hydrogen sulfide stabilized metabolic output during and after hemorrhage. CONCLUSION: These data indicate that sulfide can protect rats from lethal hemorrhage. Future studies are needed to analyze the mechanism of benefit as well as whether sulfide is beneficial in other models of human injury and disease. This article was published in J Trauma and referenced in Journal of Autacoids and Hormones

Relevant Expert PPTs

Relevant Speaker PPTs

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version